As of November 6, 2026, 7 holders' latest Schedule 13D or 13G filings report owning 5% or more of Hepion Pharmaceuticals, Inc. The largest reported stake is Vincent LoPriore's, at 26.2%. 11 filings are on record since August 14, 2025 (Schedule 13D/A, August 20, 2026).
Sell to companies like Hepion Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Gravitas Collective Corp. · Sole voting: 25,000,000 · Shared voting: 0 · Sole dispositive: 25,000,000 · Shared dispositive: 0 · SCHEDULE 13D, 2026-10-26
- · Reporting person: Kenneth Rickel · Sole voting: 7,250,000 · Shared voting: 0 · Sole dispositive: 7,250,000 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-21
- · Reporting person: KI Holdings Ltd. · Sole voting: 10,000,000 · Shared voting: 0 · Sole dispositive: 10,000,000 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-09-16
- · Holder: Kenneth Rickel · Percent: 5.7% · SCHEDULE 13G
- · Reporting person: Gravitas Capital LP · Sole voting: 0 · Shared voting: 21,000,000 · Sole dispositive: 0 · Shared dispositive: 21,000,000 · SCHEDULE 13D/A, 2026-08-20
Hepion Pharmaceuticals, Inc. has 11 Schedule 13D or 13G filings on record since 2025-08-14. 7 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 26.2% | 26,250,000 | SCHEDULE 13D/A, 2026-08-20 | 2026-08-03 | |
| Gravitas Collective Corp. | 19.9% | 25,000,000 | SCHEDULE 13D, 2026-10-26 | 2026-10-06 |
| Black Global 5 LLC | 11.1% | 10,000,000 | SCHEDULE 13D, 2026-08-07 | 2026-07-31 |
| KI Holdings Ltd. | 10.2% | 10,000,000 | SCHEDULE 13D/A, 2026-09-16 | 2026-08-03 |
| 7.2% | 7,250,000 | SCHEDULE 13G/A, 2026-10-21 | 2026-10-20 | |
| 5.7% | 5,250,000 | SCHEDULE 13D, 2026-08-20 | 2026-08-03 | |
| 5.7% | 5,250,000 | SCHEDULE 13D, 2026-08-20 | 2026-08-03 | |
| Anson Funds Management LP | 4.9% | 576,482 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| S.H.N. Financial Investments Ltd. | 0% | 0 | SCHEDULE 13G/A, 2025-08-14 | 2025-08-14 |
Holding shares or following this stake? See who's behind Hepion Pharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Hepion Pharmaceuticals, Inc. and the records around it.
The people at Hepion Pharmaceuticals, Inc.
- Gary Stetz, Sireesh Appajosyula and Vincent LoPriore are also named on 6 other Form D filings: Canton Strategic Holdings, Inc. (Apr 2026), Tharimmune, Inc. (Jul 2025)
Hepion Pharmaceuticals, Inc. elsewhere on the record
- Acquisition Oct 2026
- Leadership changes Aug 2026
- Company profile and every filing Aug 2026
- Form D filing Aug 2026
- Form D filing Apr 2026
- Who owns it
Companies that share a holder
- S.H.N. Financial Investments Ltd. also filed stake reports on 19 other companies: PRF Technologies Ltd. (Nov 2026), INLIF Ltd (Oct 2026), DarkIris Inc. (Oct 2026)
- Anson Funds Management LP also filed stake reports on 36 other companies: 22nd Century Group, Inc. (Aug 2026), Imperial Petroleum Inc. (Aug 2026), K Wave Media Ltd. (Aug 2026)
Watch Hepion Pharmaceuticals, Inc.
Get an email when Hepion Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Hepion Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Hepion Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Hepion Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Gravitas Capital LP | 0 | 21,000,000 | 0 | 21,000,000 | SCHEDULE 13D/A, 2026-08-20 |
| Invictus Capital Advisors Pension Plan | 5,250,000 | 0 | 5,250,000 | 0 | SCHEDULE 13D/A, 2026-08-20 |
| Vincent LoPriore | 5,250,000 | 21,000,000 | 5,250,000 | 21,000,000 | SCHEDULE 13D/A, 2026-08-20 |
| Gravitas Collective Corp. | 25,000,000 | 0 | 25,000,000 | 0 | SCHEDULE 13D, 2026-10-26 |
| Black Global 5 LLC | 10,000,000 | 0 | 10,000,000 | 0 | SCHEDULE 13D, 2026-08-07 |
| Red Global 3, LLC | 10,000,000 | 0 | 10,000,000 | 0 | SCHEDULE 13D, 2026-08-07 |
| Darin Feinstein | 10,000,000 | 0 | 10,000,000 | 0 | SCHEDULE 13D, 2026-08-07 |
| KI Holdings Ltd. | 10,000,000 | 0 | 10,000,000 | 0 | SCHEDULE 13D/A, 2026-09-16 |
| Kenneth Rickel | 7,250,000 | 0 | 7,250,000 | 0 | SCHEDULE 13G/A, 2026-10-21 |
| Gary Stetz | 5,250,000 | 0 | 5,250,000 | 0 | SCHEDULE 13D, 2026-08-20 |
| Sireesh Appajosyula | 5,250,000 | 0 | 5,250,000 | 0 | SCHEDULE 13D, 2026-08-20 |
The latest filing identifies Hepion Pharmaceuticals, Inc. by CUSIP 426897401 and gives its principal executive office as c/o Hepion Pharmaceuticals, Inc., 22 West Street, Verona, NJ 07701 (SCHEDULE 13D, 2026-10-26).
Source of funds (Item 3)
The aggregate purchase price of the shares of Common Stock beneficially owned by each of the Reporting Person was approximately $750,000.00. On April 21, 2026 Gravitas Capital LP ("Gravitas") acquired 5,000,000 shares of Common Stock of the Issuer pursuant to a Securities Purchase Agreement dated April 21, 2026 for an aggregate purchase price of $200,000. On April 21, 2026, Invictus Capital Advisors Pension Plan ("Invictus") acquired 1,250,000 shares of Common Stock of the Issuer pursuant to a Securities Purchase Agreement dated April 21, 2026 for an aggregate purchase price of $50,000.Vincent LoPriore, SCHEDULE 13D/A, 2026-08-20
On October 6, 2026, the Reporting Person received 25,000,000 shares Common Stock of the Issuer in exchange for the membership interests of Gravitas Life Sciences, Inc. solely owned by the Reporting Person.Gravitas Collective Corp., SCHEDULE 13D, 2026-10-26
On July 31, 2026, Black Global acquired the securities described herein pursuant to that certain Securities Purchase Agreement, dated July 31, 2026 (the "Securities Purchase Agreement"), by and among Hepion Pharmaceuticals, Inc. and the purchasers party thereto. Pursuant to the Securities Purchase Agreement, Black Global purchased 10,000,000 shares of Common Stock together with one warrant to purchase up to an additional 10,000,000 shares of Common Stock at an exercise price of $0.06 per share for an aggregate purchase price of $500,000.Black Global 5 LLC, SCHEDULE 13D, 2026-08-07
On August 3, 2026, KI Holdings Ltd. acquired the securities described herein pursuant to that certain Securities Purchase Agreement, dated July 31, 2026 (the "Securities Purchase Agreement"), by and among Hepion Pharmaceuticals, Inc. and the purchasers party thereto. Pursuant to the Securities Purchase Agreement, KI Holdings Ltd. purchased 10,000,000 shares of Common Stock together with one warrant to purchase up to an additional 10,000,000 shares of Common Stock at an exercise price of $0.06 per share for an aggregate purchase price of $500,000.KI Holdings Ltd., SCHEDULE 13D/A, 2026-09-16
Purpose of Transaction (Item 4)
Vincent LoPriore
The Common Stock owned by each of the Reporting Persons has been acquired for investment purposes. The Reporting Person may make further acquisitions of the Common Stock from time to time. Except for the foregoing, the Reporting Persons have no plans or proposals which relate to, or could result in, any of the matters referred to in Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2026-08-20
Black Global 5 LLC
The Reporting Persons acquired the securities for investment purposes. The Reporting Persons intends to review its investment in the Issuer on a continuing basis. Depending upon market conditions, the Issuer's business, financial condition, prospects, general economic conditions and other factors deemed relevant, the Reporting Persons may acquire additional securities of the Issuer, dispose of some or all of its securities, or maintain its current investment position. Except as described herein, the Reporting Persons do not presently have any plans or proposals that relate to or would result in any of the actions described in Items 4(a) through (j) of Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D filed 2026-08-07
Gary Stetz
The Common Stock owned by the Reporting Person was acquired for investment purposes. The Reporting Person may make further acquisitions of the Common Stock from time to time. Except for the foregoing, the Reporting Person has no plans or proposals which relate to, or could result in, any of the matters referred to in Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D filed 2026-08-20
Sireesh Appajosyula
The Common Stock owned by the Reporting Person was acquired for investment purposes. The Reporting Person may make further acquisitions of the Common Stock from time to time. Except for the foregoing, the Reporting Person has no plans or proposals which relate to, or could result in, any of the matters referred to in Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D filed 2026-08-20
KI Holdings Ltd.
The Reporting Person acquired the securities for investment purposes. The Reporting Person intends to review its investment in the Issuer on a continuing basis. Depending upon market conditions, the Issuer's business, financial condition, prospects, general economic conditions and other factors deemed relevant, the Reporting Persons may acquire additional securities of the Issuer, dispose of some or all of its securities, or maintain its current investment position. Except as described herein, the Reporting Person does not presently have any plans or proposals that relate to or would result in any of the actions described in Items 4(a) through (j) of Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2026-09-16
Gravitas Collective Corp.
The Common Stock owned by the Reporting Person was acquired for investment purposes. The Reporting Person may make further acquisitions of the Common Stock from time to time. Except for the foregoing, the Reporting Person has no plans or proposals which relate to, or could result in, any of the matters referred to in Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D filed 2026-10-26
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Anson Funds Management LP | 4.9% | SCHEDULE 13G/A |
| 2025-08-14 | S.H.N. Financial Investments Ltd. | 0% | SCHEDULE 13G/A |
| 2026-05-01 | Vincent LoPriore | 21.46% | SCHEDULE 13D |
| 2026-08-07 | Black Global 5 LLC | 11.1% | SCHEDULE 13D |
| 2026-08-20 | Gary Stetz | 5.7% | SCHEDULE 13D |
| 2026-08-20 | Sireesh Appajosyula | 5.7% | SCHEDULE 13D |
| 2026-08-20 | Vincent LoPriore | 26.2% | SCHEDULE 13D/A |
| 2026-09-15 | Kenneth Rickel | 5.7% | SCHEDULE 13G |
| 2026-09-16 | KI Holdings Ltd. | 10.2% | SCHEDULE 13D/A |
| 2026-10-21 | Kenneth Rickel | 7.2% | SCHEDULE 13G/A |
| 2026-10-26 | Gravitas Collective Corp. | 19.9% | SCHEDULE 13D |
Questions about who owns Hepion Pharmaceuticals, Inc.
Who owns Hepion Pharmaceuticals, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of Hepion Pharmaceuticals, Inc.: Vincent LoPriore (26.2%, Schedule 13D/A, filed 2026-08-20), Gravitas Collective Corp. (19.9%, Schedule 13D, filed 2026-10-26), Black Global 5 LLC (11.1%, Schedule 13D, filed 2026-08-07), KI Holdings Ltd. (10.2%, Schedule 13D/A, filed 2026-09-16) and Kenneth Rickel (7.2%, Schedule 13G/A, filed 2026-10-21); 2 more are listed above.
Who are the largest shareholders of Hepion Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Hepion Pharmaceuticals, Inc. on this page are Vincent LoPriore (26.2%), Gravitas Collective Corp. (19.9%) and Black Global 5 LLC (11.1%).
When did Vincent LoPriore buy into Hepion Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Vincent LoPriore on this page is the Schedule 13D, filed 2026-05-01, reporting 21.46%; its latest, Schedule 13D/A filed 2026-08-20, reports 26.2%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Hepion Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 9, 2026 | Leadership change: Gary Stetz appointed, Chief Financial Officer | — | Leadership changes | Source |
| October 6, 2026 | Acquired Gravitas Life Sciences, LLC | $2.25M | Acquisition | Source |
| August 20, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| August 5, 2026 | Form D, private offering | $3.06M sold | Form D page | Source |
| July 2, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| April 22, 2026 | Form D, private offering | $700K sold | Form D page | Source |
Hepion Pharmaceuticals, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Hepion Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.